Innovating Airway Solutions

About Breethwell: Breathing Better, Living Better

 

At Breethwell, we’re on a mission to revolutionize respiratory wellness by confronting a hidden health crisis: Day Apnea®, the subconscious breath-holding or shallow breathing that affects millions daily. Founded on over 20 years of pioneering research, Breethwell is bringing the CMAP (Continuously Monitoring Airway Pressure) device to the world, a patented, wearable IoT solution set to launch in early 2026. By empowering individuals, breathwork apps, wellness brands, and sleep apnea leaders, we’re redefining how the world breathes, one inhale at a time.

 

 

Our Story

​

Breethwell’s journey began with a personal struggle: decades of tinnitus and drug-resistant hypertension revealed a startling truth, unconscious breath-holding during everyday tasks, like screen use, was driving fatigue, stress, and health risks. This discovery, coined Day Apnea, sparked the creation of the Pacific Neuroscience Institute in 2008, where research with thousands of sufferers, particularly veterans, uncovered a common thread: irregular breathing amplified conditions like tinnitus, PTSD, and anxiety. From this insight, Breethwell was born to develop a tool that makes invisible breathing patterns visible and actionable, transforming lives across wellness and healthcare.

 

 

The Science of CMAP

 

The CMAP device is the heart of our vision. Unlike bulky chest-band monitors (e.g., CapnoTrainer, $2,950) or sleep-focused CPAP machines ($3,969.5M market, 2024), CMAP uses a precise nasal/oral cannula to track airflow, heart rate, and blood oxygen (SpO₂) in real-time. This compact (2” x 2.5” x 0.75”) device connects via Bluetooth to a smartphone app, delivering alerts for breath-holding and guided exercises to restore healthy breathing. Early tests showed nearly all users exhibit Day Apnea, with promising reductions in blood pressure and anxiety (Breethwell data, 2024). Backed by studies linking dysfunctional breathing to cardiovascular risks (Frontiers in Physiology, 2018) and a 2007 Microsoft study (40% hold breath while emailing), CMAP addresses a crisis affecting 25 million with tinnitus, 13 million with PTSD, and 19.1 million with anxiety.

 

 

 

Our Impact

 

Breethwell’s CMAP is a versatile platform serving multiple verticals:

 

Breathwork & Wellness: Partners with apps like Headspace and Breathwrk, enhancing meditation and pranayama in a booming wellness sector (Global Wellness Summit, 2021).

 

Sleep Apnea Solutions: Complements leaders like ResMed, offering daytime monitoring and potential home sleep apnea tests (HSAT) outside the U.S.

 

Therapy & Healthcare: Targets FDA-approved treatments for hypertension and anxiety, following Resperate’s success (35,000 units sold, 2023).

 

Fitness & Pain Management: Optimizes athletic performance and supports stress relief.

 

With U.S. and international patents pending and an affordable price ($299–$499), CMAP empowers individuals, workplaces, and researchers to combat Screen Apnea, prevalent among the 62% of Americans spending 4+ hours on screens daily (Common Sense Media, 2024).

 

​

Our Vision

 

Breethwell envisions a world where every breath is intentional and healing. We’re building partnerships with breathwork platforms, wellness brands, sleep apnea innovators, and healthcare providers to make CMAP a cornerstone of respiratory health. From corporate wellness programs to clinical studies, our goal is to address a silent epidemic and unlock the transformative power of breath for millions.

 

​

Join Us

 

Be part of the breathing revolution. Whether you’re a user, partner, or advocate, connect with us at info@pacneurosci.com to learn how Breethwell is making every breath count.